Innoviva, Inc. (INVA)
22.62
+0.18
(+0.80%)
USD |
NASDAQ |
Feb 13, 13:55
Innoviva Cash from Investing (Quarterly) : 18.41M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Nektar Therapeutics | -94.87M |
| Oramed Pharmaceuticals, Inc. | 38.84M |
| Theravance Biopharma, Inc. | -100.25M |
| Axsome Therapeutics, Inc. | -0.058M |
| Keros Therapeutics, Inc. | -0.132M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 49.73M |
| Cash from Financing (Quarterly) | 10.84M |
| Free Cash Flow | 196.54M |
| Free Cash Flow Per Share (Quarterly) | 0.5721 |
| Free Cash Flow to Equity (Quarterly) | 306.97M |
| Free Cash Flow to Firm (Quarterly) | 52.30M |
| Free Cash Flow Yield | 10.99% |